← Back to Search

Behavioural Intervention

Near-Infrared Light Stimulation for ADHD

N/A
Recruiting
Research Sponsored by University of Texas at Austin
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to two months
Awards & highlights

Study Summary

This trial studies how transcranial photobiomodulation (tPBM) can improve attention in healthy adults and those with ADHD. It uses a computer-based test (CPT-3) to measure if tPBM can help inattention, impulsivity, and sustained attention.

Who is the study for?
This trial is for adults over the age of 18 who may have attention issues, such as ADHD or cognitive impairment. It's designed to see if a non-invasive light therapy can help improve their attention and cognition.Check my eligibility
What is being tested?
The study tests Transcranial photobiomodulation (tPBM), a type of light therapy aimed at activating the prefrontal cortex to potentially enhance brain function. Participants will be randomly assigned to receive either active tPBM or a sham (placebo) treatment.See study design
What are the potential side effects?
Since tPBM is non-invasive and has been considered safe in previous studies, significant side effects are not expected. However, individual experiences may vary.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to two months
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to two months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Continuous Performance Task
Secondary outcome measures
Functional near-infrared spectroscopy

Trial Design

4Treatment groups
Experimental Treatment
Placebo Group
Group I: tPBM, non-ADHDExperimental Treatment1 Intervention
Participants with no medical diagnosis of ADHD will be exposed to the same conditions as sham participants, with the exception that the infrared light will be turned on (treated condition).
Group II: tPBM, ADHDExperimental Treatment1 Intervention
Participants with a medical diagnosis of ADHD will be exposed to the same conditions as sham participants, with the exception that the infrared light will be turned on (treated condition).
Group III: Sham-tPBM, non-ADHDPlacebo Group1 Intervention
Participants with no medical diagnosis of ADHD will be exposed to the same conditions as treated participants, with the exception that the infrared light will be turned off (sham condition).
Group IV: Sham-tPBM, ADHDPlacebo Group1 Intervention
Participants with a medical diagnosis of ADHD will be exposed to the same conditions as treated participants, with the exception that the infrared light will be turned off (sham condition).
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Transcranial photobiomodulation
2018
N/A
~40

Find a Location

Who is running the clinical trial?

University of Texas at AustinLead Sponsor
353 Previous Clinical Trials
80,744 Total Patients Enrolled
Douglas W Barrett, Ph.D.Study DirectorUniversity of Texas at Austin

Media Library

Transcranial photobiomodulation (Behavioural Intervention) Clinical Trial Eligibility Overview. Trial Name: NCT05802680 — N/A
Attention Deficit Disorder Research Study Groups: Sham-tPBM, non-ADHD, tPBM, non-ADHD, tPBM, ADHD, Sham-tPBM, ADHD
Attention Deficit Disorder Clinical Trial 2023: Transcranial photobiomodulation Highlights & Side Effects. Trial Name: NCT05802680 — N/A
Transcranial photobiomodulation (Behavioural Intervention) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05802680 — N/A
Attention Deficit Disorder Patient Testimony for trial: Trial Name: NCT05802680 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the ceiling of participants in this research project?

"Affirmative. The online resource clinicaltrials.gov illustrates that this medical trial, which was first advertised on February 9th 2022, is actively recruiting patients to participate. 500 individuals need to be signed up from a single site."

Answered by AI

Does this experiment have an open call for participants?

"According to clinicaltrials.gov, enrollment is still open for this trial which was initially opened on February 9th 2022 and most recently updated on April 3rd 2023."

Answered by AI

Who else is applying?

What state do they live in?
Minnesota
Texas
What site did they apply to?
The University of Texas at Austin
What portion of applicants met pre-screening criteria?
Did not meet criteria
Met criteria
How many prior treatments have patients received?
1

Why did patients apply to this trial?

I’ve never tried any drugs for this condition I was recently diagnosed for the second time.
PatientReceived 2+ prior treatments
I am past the 50 mark and seen only slight improvements and methylphenidate barely works and only intermittently.
PatientReceived no prior treatments
I've been medicated for anxiety and bipolar depression for about ten years and my current medications seem to be losing effectiveness. I'm overdue for either changing or adjusting the dose, so being involved with a useful study and potentially finding new, helpful meds sounds good.
PatientReceived 1 prior treatment

How responsive is this trial?

Typically responds via
Email
Most responsive sites:
  1. The University of Texas at Austin: < 48 hours
Average response time
  • < 2 Days
Recent research and studies
clinicaltrials.govStudy
Neurocognitive Effects of Non-Invasive Near-Infrared Light Stimulation
Francisco Gonzalez-Lima, PhD 2022. "Neurocognitive Effects of Non-Invasive Near-Infrared Light Stimulation". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05802680.
~118 spots leftby Dec 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top